Commonwealth Equity Services, LLC Cullinan Oncology, Inc. Transaction History

Commonwealth Equity Services, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 06, 2025	SELL	$7.13 - $9.08 $3,286 - $4,185	-461 Reduced 3.04%	14,699 $111,000
Q1 2025 May 09, 2025	BUY	$7.57 - $12.68 $4,965 - $8,318	656 Added 4.52%	15,160 $115,000
Q4 2024 Feb 10, 2025	SELL	$10.77 - $17.6 $1,077 - $1,760	-100 Reduced 0.68%	14,504 $177,000
Q2 2024 Jul 31, 2024	SELL	$15.63 - $29.35 $1,563 - $2,935	-100 Reduced 0.68%	14,604 $255,000
Q1 2024 Apr 29, 2024	SELL	$10.17 - $19.02 $63,613 - $118,970	-6,255 Reduced 29.84%	14,704 $251,000

Q2 2023 Aug 10, 2023	BUY	$8.8 - $13.4 $184,439 - $280,850	20,959 New	20,959 $226,000

149

65.1M

10.7K

14.4K

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $390M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.